Cellectis (CLLS) Total Non-Current Liabilities (2014 - 2026)

Cellectis (CLLS) recorded quarterly Total Non-Current Liabilities of $94.8 million in Q1 2026, down 8.05% quarter-over-quarter from $103.1 million in Q4 2025, and up 11.08% on a YoY basis from $85.3 million in Q1 2025.

Cellectis (CLLS) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends

Cellectis' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $94.8 million for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities rose 11.08% year-over-year to $94.8 million; the TTM figure through Mar 2026 stood at $94.8 million (up 11.08% YoY), while the FY2025 annual figure was $103.1 million, up 19.51% from the prior year.
  • Total Non-Current Liabilities was $94.8 million for Q1 2026 at Cellectis, down from $103.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $105.4 million in Q1 2024 to a low of $70.4 million in Q1 2023.
  • Historically, Total Non-Current Liabilities has averaged $90.1 million across 5 years, with a median of $89.6 million in 2023.
  • The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities declined 24.91% in 2022, then surged 49.67% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $72.3 million in 2022, then soared by 30.65% to $94.4 million in 2023, then dropped by 8.67% to $86.2 million in 2024, then increased by 19.51% to $103.1 million in 2025, then fell by 8.05% to $94.8 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $94.8 million (Q1 2026), $103.1 million (Q4 2025), and $94.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 42,980.09
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 11.03 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 95.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 644,700.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.96 Bn 91.96 Bn - 64.76 Mn
10 Cellectis 17.40 Bn 17.21 Bn - 94.77 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 94.77 Mn
Dec 31, 2025 103.07 Mn
Sep 30, 2025 93.99 Mn
Jun 30, 2025 89.42 Mn
Mar 31, 2025 85.31 Mn
Dec 31, 2024 86.24 Mn
Sep 30, 2024 100.80 Mn
Jun 30, 2024 98.90 Mn
Mar 31, 2024 105.45 Mn
Dec 31, 2023 94.43 Mn
Sep 30, 2023 89.63 Mn
Jun 30, 2023 89.07 Mn
Mar 31, 2023 70.45 Mn
Dec 31, 2022 72.28 Mn
Sep 30, 2022 80.94 Mn
Jun 30, 2022 85.08 Mn
Mar 31, 2022 91.80 Mn
Dec 31, 2021 96.25 Mn
Sep 30, 2021 101.14 Mn
Jun 30, 2021 103.80 Mn